ACIP Includes Fluad Quadrivalent as a Preferentially Recommended Influenza Vaccine for Adults Over 65

The preferential recommendation is built on research and real-world data

Following a review of randomized studies and real-world data from many influenza seasons, the CDC’s Advisory Committee on Immunization Practices (ACIP) will include the Seqirus FluadQuadrivalent vaccine as a preferentially recommended season influenza vaccine for individuals aged 65 years and old. This recommendation is built on the clinical benefits compared to the standard egg-based influenza vaccines. If a preferentially recommended vaccine is not available at the time of administration, any age-appropriate vaccine should be used.

To address the immunosenescence that may lead to a reduction in immune response to vaccines, the Fluad Quadrivalent vaccine uses the MF59 adjuvant to strengthen the immune response. More than 225 million doses have been administered since its approval in 1997, illustrating the safety and efficacy of the vaccine.

Gregg Sylvester, MD, Chief Health Officer at Seqirus said in a news release, "It is critical that we do everything we can to protect vulnerable populations like older adults against influenza. Today's recommendation is evidence of the ACIP's commitment to providing clear, evidence-backed guidance to protect public health. We are proud to offer one of the enhanced flu vaccines that was preferentially recommended by the ACIP for adults 65 years and above in the United States."


CDC advisory committee includes Fluad® Quadrivalent as a preferentially recommended influenza vaccine for adults 65 and older. News Release. Seqirus.June 22, 2022. Accessed June 23, 2022.